Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.
作者信息
Kuypers Dirk R J, Vanhove Thomas
机构信息
Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium.
出版信息
Br J Clin Pharmacol. 2018 Jul;84(7):1622-1623. doi: 10.1111/bcp.13592. Epub 2018 Apr 24.
Abstract
摘要
相似文献
1
Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.凯珀斯和范霍夫对诺伊霍夫和塔克所著的《4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？》一文作出回应。
Br J Clin Pharmacol. 2018 Jul;84(7):1622-1623. doi: 10.1111/bcp.13592. Epub 2018 Apr 24.
2
Gjestad et al. reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.杰斯塔德等人对纽霍夫和塔克所著的《4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？》一文的回应。
Br J Clin Pharmacol. 2018 Jul;84(7):1624-1625. doi: 10.1111/bcp.13606. Epub 2018 May 10.
3
Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？
Br J Clin Pharmacol. 2018 Jul;84(7):1620-1621. doi: 10.1111/bcp.13538. Epub 2018 Feb 21.
4
Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.评价 4β-羟胆固醇和 25-羟胆固醇作为 CYP3A4 内源性生物标志物的研究：用 CYP3A 人源化小鼠进行的研究。
AAPS J. 2018 Apr 9;20(3):61. doi: 10.1208/s12248-018-0186-9.
5
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.4β-羟基胆固醇，一种人体内 CYP3A4/5 活性的内源性标志物。
Br J Clin Pharmacol. 2011 Feb;71(2):183-9. doi: 10.1111/j.1365-2125.2010.03773.x.
6
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.4β-羟基胆固醇作为CYP3A4/5活性的内源性标志物。利福平诱导后消除的稳定性和半衰期。
Br J Clin Pharmacol. 2009 Jan;67(1):38-43. doi: 10.1111/j.1365-2125.2008.03309.x. Epub 2008 Nov 6.
7
Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time.内源性4β-羟基胆固醇作为评估细胞色素P450 3A（CYP3A）活性生物标志物的效用：尚未完全准备好进入黄金时期。
Eur J Clin Pharmacol. 2022 Nov;78(11):1863-1864. doi: 10.1007/s00228-022-03386-z. Epub 2022 Sep 13.
8
CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine.产后早期基于血浆4β-羟基胆固醇的CYP3A活性对氨氯地平的血浆处置有影响。
Drug Metab Pharmacokinet. 2015 Dec;30(6):419-24. doi: 10.1016/j.dmpk.2015.08.008. Epub 2015 Sep 3.
9
Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy.卡马西平治疗小儿癫痫患者期间4β-羟基胆固醇浓度升高的时间进程。
Br J Clin Pharmacol. 2008 May;65(5):708-15. doi: 10.1111/j.1365-2125.2007.03078.x. Epub 2008 Feb 12.
10
Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity.基于一种新方法提高 4β-羟基胆固醇作为 CYP3A4 活性生物标志物测量准确性的临床评估。
Molecules. 2023 Feb 7;28(4):1576. doi: 10.3390/molecules28041576.
引用本文的文献
1
Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.4β-羟胆固醇与肝和肠道 CYP3A4 的相关性：在广泛体重范围内的患者中的蛋白表达、离体 microsomal 活性和体内活性。
Eur J Clin Pharmacol. 2022 Aug;78(8):1289-1299. doi: 10.1007/s00228-022-03336-9. Epub 2022 Jun 1.
本文引用的文献
1
Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？
Br J Clin Pharmacol. 2018 Jul;84(7):1620-1621. doi: 10.1111/bcp.13538. Epub 2018 Feb 21.
2
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.2018 年 IUPHAR/BPS 药理学指南：更新和扩展，以包含新的免疫药理学指南。
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. doi: 10.1093/nar/gkx1121.
3
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters.2017/18 年药理学简明指南：转运蛋白。
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S360-S446. doi: 10.1111/bph.13883.
4
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.《药理学简明指南 2017/18：酶》
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S272-S359. doi: 10.1111/bph.13877.
5
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors.2017/18 年简明药理学指南：核激素受体。
Br J Pharmacol. 2017 Dec;174 Suppl 1(Suppl Suppl 1):S208-S224. doi: 10.1111/bph.13880.
6
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.移植前 4β-羟基胆固醇不能预测肾移植后最初几天他克莫司的暴露或剂量需求。
Br J Clin Pharmacol. 2017 Nov;83(11):2406-2415. doi: 10.1111/bcp.13343. Epub 2017 Jul 14.
7
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.细胞色素P450 3A（CYP3A）生物标志物4β-羟基胆固醇并不能改善肾移植术后早期他克莫司剂量的预测。
Br J Clin Pharmacol. 2017 Jul;83(7):1457-1465. doi: 10.1111/bcp.13248. Epub 2017 Feb 27.
8
Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.口服咪达唑仑清除率与血浆4β-羟基胆固醇在解释他克莫司清除率个体间差异方面的比较性能。
Br J Clin Pharmacol. 2016 Dec;82(6):1539-1549. doi: 10.1111/bcp.13083. Epub 2016 Sep 20.
9
Pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known?
Clin Pharmacol Ther. 2013 Apr;93(4):306-7. doi: 10.1038/clpt.2012.214. Epub 2012 Oct 24.
10
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?血浆4β-羟基胆固醇：一种内源性CYP3A指标？
Clin Pharmacol Ther. 2009 Aug;86(2):147-53. doi: 10.1038/clpt.2009.72. Epub 2009 May 20.
Zotero 插件